^
    Back
    Association details:
    Biomarker:MHC-II overexpression + PD-L1 underexpression
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Thorac Oncol
    Title:

    Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study

    Published date:
    08/03/2021
    Excerpt:
    In this study, 397 previously untreated, locally advanced or metastatic non-squamous NSCLC patients received sintilimab plus chemotherapy (combo group) or placebo plus chemotherapy (chemo group)....patients with low or absent PD-L1 but high MHC-II expression could still benefit from the combo treatment.
    DOI:
    10.1016/j.jtho.2021.07.015
    Trial ID:
    ORIENT-11